KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Finished Goods: 2009-2025

Historic Finished Goods for Halozyme Therapeutics (HALO) over the last 13 years, with Sep 2025 value amounting to $161.6 million.

  • Halozyme Therapeutics' Finished Goods rose 12.59% to $161.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.6 million, marking a year-over-year increase of 12.59%. This contributed to the annual value of $142.9 million for FY2024, which is 104.41% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Finished Goods of $161.6 million as of Q3 2025, which was down 1.99% from $164.9 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Finished Goods high stood at $164.9 million for Q2 2025, and its period low was $25.8 million during Q4 2021.
  • Moreover, its 3-year median value for Finished Goods was $126.6 million (2024), whereas its average is $111.7 million.
  • Data for Halozyme Therapeutics' Finished Goods shows a peak YoY increase of 200.99% (in 2021) and a maximum YoY decrease of 16.39% (in 2021) over the last 5 years.
  • Halozyme Therapeutics' Finished Goods (Quarterly) stood at $25.8 million in 2021, then skyrocketed by 78.28% to $46.0 million in 2022, then spiked by 52.12% to $69.9 million in 2023, then spiked by 104.41% to $142.9 million in 2024, then increased by 12.59% to $161.6 million in 2025.
  • Its last three reported values are $161.6 million in Q3 2025, $164.9 million for Q2 2025, and $143.2 million during Q1 2025.